Contrary to this result, it has been reported that double inhibition of the EGFR and the FGFR in non-small cell lung cancer inhibit the survival and expansion of drug-resistant cells with EGFR mutations over a long period of time [42]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.